Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech

EDMONTON, Alberta, June 10, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) ('Quest' or the 'Company'), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, announced today that Quest was not informed or consulted, opposes and will not support the recently announced acquisition by privately held South Korea-based OQPBIOM Inc. ('OQM') of a controlling interest in AdBioTech Co., Ltd. ('AdBioTech'), a public company listed on KOSDAQ in South Korea. OQM has announced that AdBioTech is the corporate vehicle through which it wishes to pursue the funding and advancement of its immunotherapy assets.
As announced by Quest on June 2, 2025, as a result of the conversion of bonds, Quest has acquired a 26.25% share ownership interest in OQM and become its largest shareholder. OQM was established in April 2024 to conduct clinical trials for oregovomab, a novel ovarian cancer drug candidate, which was developed by Quest investee company, OncoQuest Inc., and sold in 2020, which ultimately resulted in Quest holding the bonds in OQM that were recently converted.
Dr. Madi Madiyalakan, CEO of Quest, stated, "As the largest shareholder of OQM, we were never informed or consulted about OQM's acquisition of a controlling interest in AdBioTech and OQM's intention to use this vehicle to advance oregovomab." He added that Quest strongly opposes this acquisition and strategy, deeming it inappropriate for ensuring stable funding for oregovomab's clinical trials and not in the best interest of OQM or its shareholders. Quest is consulting with its advisors and evaluating its legal options. Any information or reports disseminated that suggest that Quest is supportive of OQM management in the implementation of this path and strategy for OQM is inaccurate.
About Quest PharmaTech Inc.
Quest PharmaTech Inc is a publicly traded, Canadian based biopharmaceutical company (QPT: TSX-V) developing products to improve the quality of life. The Company has a 42.5% ownership interest in OncoQuest Inc. which sold its immunotherapy technology assets to Korea-based Dual Industrial Co, Ltd. in April 2020. Quest also has a 23% ownership interest in OncoVent, a Chinese joint venture developing antibody-based immunotherapeutic products for cancer for the Greater China territory. Quest is also developing proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. AR 9.6 was licensed from University of Nebraska and currently is in late preclinical stage. To learn more, visit www.questpharmatech.com.
Forward Looking Statements
This news release contains 'forward-looking information' within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as 'may', 'expect', 'likely', 'should', 'would', 'plan', 'anticipate', 'intend', 'potential', 'proposed', 'estimate', 'believe' or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions 'may' or 'will' happen. The forward-looking information contained herein is made as of the date of this press release and is based on assumptions management believed to be reasonable at the time such statements were made. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation, the risk factors that can be found in the Company's securities law filings which have been filed under the Company's SEDAR+ profile at www.sedarplus.ca. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
For further information: Dr. Madi R. Madiyalakan, CEO, Quest PharmaTech Inc. Tel: (780) 448-1400, E-mail: madi@questpharmatech.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

39 minutes ago

• Yahoo

Invest $20,000 in a TSX Stock, Create $1,278.98 in Passive Income

Written by Amy Legate-Wolfe at The Motley Fool Canada When inflation is high and the cost of living keeps climbing, reliable income from investments becomes more important than ever. One of the best ways to generate this income is through dividend-paying stocks on the TSX. And if I had $20,000 to invest right now, I'd seriously consider putting it into Peyto Exploration & Development (TSX:PEY). This dividend-paying energy stock offers both stability and strong returns, especially for those looking to boost their monthly cash flow. Peyto is one of Canada's most established natural gas producers. Based in Alberta, it focuses on exploration and development in the Deep Basin, an area rich in natural gas and natural gas liquids. What sets it apart is how efficiently it runs its operations. The dividend stock built a reputation for keeping costs low and margins strong. That gives it the flexibility to return more cash to shareholders, something that's especially appealing in a world where interest rates are uncertain and recession fears loom. Right now, Peyto trades for about $20.60 per share. Its annual dividend sits at $1.32 per share, which works out to a dividend yield of around 6.4%. That's far above the TSX average. So, if you were to invest $20,000 at today's price, you could buy 969 shares. At $1.32 per share annually, that means you'd receive almost $1,280 in passive income each year. That's about $107 every single month just for holding the dividend stock! COMPANY RECENT PRICE NUMBER OF SHARES DIVIDEND TOTAL PAYOUT FREQUENCY INVESTED AMOUNT PEY $20.62 969 $1.32 $1,278.98 Monthly $19,982.78 That level of income is especially appealing inside a TFSA. Because dividends in a TFSA are tax-free, every dollar of that $1,280 stays in your pocket. You don't have to worry about tax slips or losing part of your income to the Canada Revenue Agency (CRA). It's one of the most efficient ways to generate passive income in Canada, and Peyto fits perfectly into that strategy. Looking at the company's most recent earnings, Peyto continues to perform well. In the first quarter of 2025, it reported revenue of $323.8 million and earnings per share (EPS) of $0.57. While natural gas prices have come down from their highs, Peyto remains profitable and has kept its payout ratio in check. Over the last twelve months, earnings per share came in at $1.48. This means its current dividend payout is comfortably below earnings, which suggests that the dividend is sustainable. Peyto also pays its dividend monthly, which makes budgeting much easier for investors looking to build consistent cash flow. The monthly payout has held steady at $0.11 per share for the last 12 months. That consistency is hard to find, especially in the energy sector, where prices can swing wildly. But Peyto's disciplined approach to debt and cost control helps it ride out the cycles more smoothly than some of its peers. Of course, no investment is risk-free. Peyto's business is tied closely to the price of natural gas. If prices fall sharply, earnings could take a hit. But management has a solid track record of adjusting capital spending and maintaining flexibility when needed. And even during tough times, it has shown a strong commitment to preserving its dividend. In short, if you're looking to put $20,000 to work in a way that generates meaningful monthly income, Peyto is worth a close look. With its 6.4% yield, monthly payouts, and reliable operations, it stands out as a solid TSX stock for passive income. That $1,280 a year could go a long way toward covering bills, topping up savings, or simply helping you feel more financially secure. And in times like these, that kind of peace of mind is hard to beat. The post Invest $20,000 in a TSX Stock, Create $1,278.98 in Passive Income appeared first on The Motley Fool Canada. More reading Made in Canada: 5 Homegrown Stocks Ready for the 'Buy Local' Revolution [PREMIUM PICKS] Market Volatility Toolkit Best Canadian Stocks to Buy in 2025 Beginner Investors: 4 Top Canadian Stocks to Buy for 2025 5 Years From Now, You'll Probably Wish You Grabbed These Stocks Subscribe to Motley Fool Canada on YouTube Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. 2025 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Associated Press

2 hours ago

• Associated Press

IBN Coverage: D-Wave Quantum (NYSE: QBTS) Signs MOU to Advance Quantum Computing in South Korea

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - June 20, 2025 ( NEWMEDIAWIRE ) - D-Wave Quantum Inc. (NYSE: QBTS) ('D-Wave'), a leader in quantum computing systems, software, and services, announced that it has signed a memorandum of understanding (MOU) with Yonsei University and Incheon Metropolitan City aimed at accelerating quantum computing adoption in South Korea. Supporting the region's ambition to become a global quantum technology hub, the MOU outlines plans to work together on research, talent development, and use case exploration across biotechnology, materials science and other sectors. The MOU also facilitates the organizations' collaborative efforts towards the acquisition of a D-Wave Advantage2 quantum system at the Yonsei University International Campus in Songdo, Yeonsu-gu, Incheon. To view the full press release, visit About D-Wave Quantum Inc. D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world's first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our quantum computers, the world's largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our quantum systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we're shaping the quantum-driven industrial and societal advancements of tomorrow: Forward Looking Statements Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law. NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: The latest news and updates relating to QBTS are available in the company's newsroom at Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. About IBN IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients. IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Media Contact IBN Los Angeles, California 310.299.1717 Office [email protected]

The Verge

3 hours ago

• The Verge

Meta held talks to buy Thinking Machines, Perplexity, and Safe Superintelligence

At this point, it's becoming easier to say which AI startups Mark Zuckerberg hasn't looked at acquiring. In addition to Ilya Sutskever's Safe Superintelligence (SSI), sources tell me the Meta CEO recently discussed buying ex-OpenAI CTO Mira Murati's Thinking Machines Lab and Perplexity, the AI-native Google rival. None of these talks progressed to the formal offer stage for various reasons, including disagreements over deal prices and strategy, but together they illustrate how aggressively Zuckerberg has been canvassing the industry to reboot his AI efforts. Now, details about the team Zuckerberg is assembling are starting to come into view: SSI co-founder and CEO Daniel Gross, along with ex-Github CEO Nat Friedman, are poised to co-lead the Meta AI assistant. Both men will report to Alexandr Wang, the former Scale CEO Zuckerberg just paid over $14 billion to quickly hire. Wang told his Scale team goodbye last Friday and was in the Meta office on Monday. This week, he has been meeting with top Meta leaders (more on that below) and continuing to recruit for the new AI team Zuckerberg has tasked him with building. I expect the team to be unveiled as soon as next week. Rather than join Meta, Sutskever, Murati, and Perplexity CEO Aravind Srinivas have all gone on to raise more money at higher valuations. Sutskever, a titan of the AI research community who co-founded OpenAI, recently raised a couple of billion dollars for SSI. Both Meta and Google are investors in his company, I'm told. Murati also just raised a couple of billion dollars. Neither she nor Sutskever is close to releasing a product. Srinivas, meanwhile, is in the process of raising around $500 million for Perplexity. Spokespeople for all the companies involved either declined to comment or didn't respond in time for publication. The Information and CNBC first reported Zuckerberg's talks with Safe Superintelligence, while Bloomberg first reported the Perplexity talks. While Zuckerberg's recruiting drive is motivated by the urgency he feels to fix Meta's AI strategy, the situation also highlights the fierce competition for top AI talent these days. In my conversations this week, those on the inside of the industry aren't surprised by Zuckerberg making nine-figure — or even, yes, 10-figure — compensation offers for the best AI talent. There are certain senior people at OpenAI, for example, who are already compensated in that ballpark, thanks to the company's meteoric increase in valuation over the last few years. Speaking of OpenAI, it's clear that CEO Sam Altman is at least a bit rattled by Zuckerberg's hiring spree. His decision to appear on his brother's podcast this week and say that 'none of our best people' are leaving for Meta was probably meant to convey a position of strength, but in reality, it looks like he is throwing his former colleagues under the bus. I was confused by Altman's suggestion that Meta paying a lot upfront for talent won't 'set up a great culture.' After all, didn't OpenAI just pay $6.5 billion to hire Jony Ive and his small hardware team? When I joined a Zoom call with Alex Himel, Meta's VP of wearables, this week, he had just gotten off a call with Zuckerberg's new AI chief, Alexandr Wang. 'There's an increasing number of Alexes that I talk to on a regular basis,' Himel joked as we started our conversation about Meta's new glasses release with Oakley. 'I was just in my first meeting with him. There were like three people in a room with the camera real far away, and I was like, 'Who is talking right now?' And then I was like, 'Oh, hey, it's Alex.'' The following Q&A has been edited for length and clarity: How did your meeting with Alex just now go? The meeting was about how to make AI as awesome as it can be for glasses. Obviously, there are some unique use cases in the glasses that aren't stuff you do on a phone. The thing we're trying to figure out is how to balance it all, because AI can be everything to everyone or it could be amazing for more specific use cases. We're trying to figure out how to strike the right balance because there's a ton of stuff in the underlying Llama models and that whole pipeline that we don't care about on glasses. Then there's stuff we really, really care about, like egocentric view and trying to feed video into the models to help with some of the really aspirational use cases that we wouldn't build otherwise. You are referring to this new lineup with Oakley as 'AI glasses.' Is that the new branding for this category? They are AI glasses, not smart glasses? We refer to the category as AI glasses. You saw Orion. You used it for longer than anyone else in the demo, which I commend you for. We used to think that's what you needed to hit scale for this new category. You needed the big field of view and display to overlay virtual content. Our opinion of that has definitely changed. We think we can hit scale faster, and AI is the reason we think that's possible. Right now, the top two use cases for the glasses are audio — phone calls, music, podcasts — and taking photos and videos. We look at participation rates of our active users, and those have been one and two since launch. Audio is one. A very close second is photos and videos. AI has been number three from the start. As we've been launching more markets — we're now in 18 — and we've been adding more features, AI is creeping up. Our biggest investment by a mile on the software side is AI functionality, because we think that glasses are the best form factor for AI. They are something you're already wearing all the time. They can see what you see. They can hear what you hear. They're super accessible. Is your goal to have AI supersede audio and photo to be the most used feature for glasses, or is that not how you think about it? From a math standpoint, at best, you could tie. We do want AI to be something that's increasingly used by more people more frequently. We think there's definitely room for the audio to get better. There's definitely room for image quality to get better. The AI stuff has much more headroom. How much of the AI is onboard the glasses versus the cloud? I imagine you have lots of physical constraints with this kind of device. We've now got one billion-parameter models that can run on the frame. So, increasingly, there's stuff there. Then we have stuff running on the phone. If you were watching WWDC, Apple made a couple of announcements that we haven't had a chance to test yet, but we're excited about. One is the Wi-Fi Aware APIs. We should be able to transfer photos and videos without having people tap that annoying dialogue box every time. That'd be great. The second one was processor background access, which should allow us to do image processing when you transfer the media over. Syncing would work just like it does on Android. Do you think the market for these new Oakley glasses will be as big as the Ray-Bans? Or is it more niche because they are more outdoors and athlete-focused? We work with EssilorLuxottica, which is a great partner. Ray-Ban is their largest brand. Within that, the most popular style is Wayfair. When we launched the original Ray-Ban Meta glasses, we went with the most popular style for the most popular brand. Their second biggest brand is Oakley. A lot of people wear them. The Holbrook is really popular. The HSTN, which is what we're launching, is a really popular analog frame. We increasingly see people using the Ray-Ban Meta glasses for active use cases. This is our first step into the performance category. There's more to come. What's your reaction to Google's announcements at I/O for their XR glasses platform and eyewear partnerships? We've been working with EssilorLuxottica for like five years now. That's a long time for a partnership. It takes a while to get really in sync. I feel very good about the state of our partnership. We're able to work quickly. The Oakley Meta glasses are the fastest program we've had by quite a bit. It took less than nine months. I thought the demos they [Google] did were pretty good. I thought some of those were pretty compelling. They didn't announce a product, so I can't react specifically to what they're doing. It's flattering that people see the traction we're getting and want to jump in as well. On the AR glasses front, what have you been learning from Orion now that you've been showing it to the outside world? We've been going full speed on that. We've actually hit some pretty good internal milestones for the next version of it, which is the one we plan to sell. The biggest learning from using them is that we feel increasingly good about the input and interaction model with eye tracking and the neural band. I wore mine during March Madness in the office. I was literally watching the games. Picture yourself sitting at a table with a virtual TV just above people's heads. It was amazing. More to click on: If you haven't already, don't forget to subscribe to The Verge, which includes unlimited access to Command Line and all of our reporting. As always, I welcome your feedback, especially if you've also turned down Zuck. You can respond here or ping me securely on Signal. Thanks for subscribing.